The FDA has expanded the approval of Thrombate III to include pediatric patients with hATd to treat and prevent thromboembolism.
The rapid rise of GLP-1 weight loss drugs such as semaglutide and tirzepatide has created two parallel markets. One market consists of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback